2012-10-05 16:43:44 - New Pharmaceuticals market report from Global Markets Direct: "Renal Cell Carcinoma - Pipeline Review, H2 2012"

Global Markets Direct's, 'Renal Cell Carcinoma - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Renal Cell Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Renal Cell Carcinoma. Renal Cell Carcinoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.


Full Report Details at
- www.fastmr.com/prod/468436_renal_cell_carcinoma_pipeline_review_ ..


Note*: Certain sections in the report may be removed or altered based

on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Renal Cell Carcinoma.
* A review of the Renal Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Renal Cell Carcinoma pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Renal Cell Carcinoma.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Renal Cell Carcinoma pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Renal Cell Carcinoma Overview
Therapeutics Development
An Overview of Pipeline Products for Renal Cell Carcinoma
Renal Cell Carcinoma Therapeutics under Development by Companies
Renal Cell Carcinoma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Renal Cell Carcinoma Therapeutics - Products under Development by Companies
Renal Cell Carcinoma Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Renal Cell Carcinoma Therapeutics Development
Bristol-Myers Squibb Company
Boehringer Ingelheim GmbH
Kyowa Hakko Kirin Co., Ltd.
Abbott Laboratories
Amgen Inc.
AstraZeneca PLC
GlaxoSmithKline plc
Seattle Genetics, Inc.
Genentech, Inc.
Inovio Biomedical Corporation
Celltrion, Inc.
Novartis AG
Astellas Pharma Inc.
Ono Pharmaceutical Co., Ltd.
OSI Pharmaceuticals, Inc.
Pfizer Inc.
Taiho Pharmaceutical Co., Ltd.
Exelixis, Inc.
MannKind Corporation
3SBio Inc.
Hemispherx Biopharma, Inc.
arGEN-X BV
Tigris Pharmaceuticals, Inc.
KAHR medical Ltd.
n.v. BRUCELLS s.a.
Medical Enzymes AG
Ampio Pharmaceuticals, Inc.
Renal Cell Carcinoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
perifosine - Drug Profile
rilotumumab - Drug Profile
Inlyta - Drug Profile
sunitinib malate - Drug Profile
RG-7422 - Drug Profile
cediranib maleate - Drug Profile
linifanib - Drug Profile
OSI-027 - Drug Profile
MDX-1203 - Drug Profile
CDX-1127 - Drug Profile
foretinib - Drug Profile
vorsetzumab - Drug Profile
naptumomab - Drug Profile
LOR-1284 - Drug Profile
LOR-2040 - Drug Profile
MKC1106-PP - Drug Profile
IL-2 XL - Drug Profile
IMA-901 - Drug Profile
Drug Targetting CA9 - Drug Profile
cabozantinib - Drug Profile
NuLeusin - Drug Profile
JX-594 - Drug Profile
CDX-014 - Drug Profile
mepacrine - Drug Profile
Bevacizumab + Sorafenib Tosylate - Drug Profile
Sorafenib Tosylate + Temsirolimus - Drug Profile
everolimus - Drug Profile
panobinostat - Drug Profile
Tarceva + Avastin - Drug Profile
Avastin + Tarceva + Gleevec - Drug Profile
bortezomib - Drug Profile
pazopanib hydrochloride - Drug Profile
Nelfinavir + Temsirolimus - Drug Profile
TH-302 + Sunitinib - Drug Profile
AGS-16M8F - Drug Profile
interferon-alpha - Drug Profile
pazopanib hydrochloride - Drug Profile
bevacizumab - Drug Profile
Bevacizumab + Interferon-Alpha - Drug Profile
sunitinib malate - Drug Profile
sunitinib malate - Drug Profile
aldesleukin - Drug Profile
RO-4929097 - Drug Profile
sorafenib tosylate - Drug Profile
Everolimus + Sunitinib - Drug Profile
hydroxychloroquine - Drug Profile
Gemcitabine + Sunitinib - Drug Profile

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=468436&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.